Prognostic significance of combined α-fetoprotein and CA19-9 for hepatocellular carcinoma after hepatectomy

Table 2 Preoperative clinicopathological data of enrolled patients, stratified based on preoperative serum levels of AFP and CA19-9

Variable	AFP ≤ 400 ng/mL and CA19-9 ≤ 37 U/mL (n =294)	AFP > 400 ng/mL and CA19-9 ≤ 37 U/mL (n = 258)	AFP ≤ 400 ng/mL and CA19-9 > 37 U/mL (n = 87)	AFP > 400ng/mL and CA19-9 > 37 U/mL (n = 72)	P
Sex					0.005
Male	267	207	72	61
Female	27	51	15	11
Age					0.067
≤60 years	231	222	69	63
>60 years	63	36	18	9
Tumor size					0.003
<5 cm	111	68	30	14
≥5 cm	183	190	57	58
Number of tumors					0.617
<2	213	176	58	49
≥2	81	82	29	23
Tumor capsule					0.019
Complete	239	187	75	57
Incomplete	55	71	12	15
MVI					0.001
Negative	148	92	41	23
Positive	146	166	46	49
BCLC stage					<0.001
A–B	227	154	62	35
C	67	104	25	37
Edmonson grade					0.001
I–II	265	202	75	56
III–IV	29	56	12	16
HBsAg					<0.001
Negative	52	37	5	0
Positive	242	221	82	72
Liver cirrhosis					0.120
No	182	161	44	38
Yes	112	97	43	34
Child–Pugh score					0.090
A	287	255	82	71
B	7	3	5	1
Serum albumin					0.002
<35 g/L	28	26	20	13
≥35 g/L	266	232	67	59
ALT					<0.001
≤40 U/L	203	180	33	34
>40 U/L	91	78	54	38
AST					<0.001
≤40 U/L	192	144	33	23
>40 U/L	102	114	54	49
TBil					0.053
≤17.1 μmol/mL	236	213	61	53
>17.1 μmol/mL	58	45	26	19

MVI microvascular invasion, BCLC Barcelona Clinic Liver Cancer Staging System, HBsAg hepatitis B surface antigen, ALT alanine aminotransferase, AST aspartate aminotransferase, TBil total bilirub

ISSN: 1477-7819